journal article·2025-08-18Open access

Radiological and Neuroradiological Features in Pediatric Mucopolysaccharidoses: A Retrospective Case Series from the Emilia-Romagna Regional Referral Center

Giovanni Silva, Elisa Bortolamedi, Michelangelo Baldazzi, Francesco Toni, Rita Ortolano, Egidio Candela, Giacomo Biasucci, Marcello Lanari, Federico Baronio

Applied Sciences· Volume 15· Issue 16

Abstract

Background: Mucopolysaccharidoses (MPSs) are rare lysosomal storage disorders characterized by multisystem involvement; notably, skeletal abnormalities known as dysostosis multiplex and varying degrees of central nervous system impairment. Accurate radiological evaluation is crucial for accurate diagnosis and effective planning. This study aims to describe the clinical and radiological features of patients with MPS managed at our tertiary care center. Methods: We retrospectively reviewed clinical and radiological data from eight patients with confirmed MPS treated at S. Orsola University Hospital (Bologna, Italy) since 2000. Imaging included conventional radiography, supplemented by MRI and CT. The findings were analyzed by MPS subtype and correlated with clinical evolution and therapeutic interventions. A literature review complemented the analysis. Results: The cohort included one patient with MPS I, two with MPS II, one with MPS III, and four with MPS IV. Common skeletal findings were vertebral deformities, hip dysplasia, and shortening of long bones. Patients with MPS IV showed the most severe bone involvement, including pronounced platyspondyly and odontoid hypoplasia. Follow-up imaging demonstrated progression of bone and CNS pathology despite enzyme replacement therapy (ERT). Conclusions: Our findings underscore the pivotal role of imaging in MPS management. Tailored radiological protocols and multidisciplinary care are crucial for optimizing diagnosis and monitoring disease progression.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Lysosomal Storage Disorders Research · Trypanosoma species research and implications · Glycogen Storage Diseases and Myoclonus

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Specialty School of Pediatrics, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy

Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

Department of Medical and Surgical Sciences, Alma Mater Studiorum—University of Bologna, Via Massarenti, 40126 Bologna, Italy

Pediatric and Adult Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

Neuroradiology Unit, IRCCS Istituto Delle Scienze Neurologiche di Bologna, 40138 Bologna, Italy

Pediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy

Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy

References (30)

Show source-provided references
1. Biochemical and molecular analysis in mucopolysaccharidoses: What a paediatrician must know10.1186/s13052-018-0553-2 ↗
2. Musculoskeletal manifestations of lysosomal storage disorders10.1136/ard.2008.095315 ↗
3. Galimberti, C., Madeo, A., Di Rocco, M., and Fiumara, A. (2018). Mucopolysaccharidoses: Early Diagnostic Signs in Infants and Children, BioMed Central Ltd.10.1186/s13052-018-0550-5 ↗
4. The role of imaging in the skeletal involvement of mucopolysaccharidoses10.1186/s13052-018-0556-z ↗
5. Machnikowska-Sokołowska, M., Myszczuk, A., Wieszała, E., Wieja-Błach, D., Jamroz, E., and Paprocka, J. (2023). Mucopolysaccharidosis Type 1 among Children—Neuroradiological Perspective Based on Single Centre Experience and Literature Review. Metabolites, 13.10.3390/metabo13020209 ↗
6. Imaging findings of mucopolysaccharidoses: A pictorial review10.1007/s13244-013-0246-8 ↗
7. De Ponti, G., Donsante, S., Frigeni, M., Pievani, A., Corsi, A., Bernardo, M.E., Riminucci, M., and Serafini, M. (2022). MPSI Manifestations and Treatment Outcome: Skeletal Focus. Int. J. Mol. Sci., 23.10.3390/ijms231911168 ↗
8. The natural history of MPS I: Global perspectives from the MPS I Registry10.1038/gim.2014.25 ↗
9. Blau, N., Duran, M., Gibson, K.M., and Vici, C.D. (2022). Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases, Springer International Publishing.10.1007/978-3-030-67727-5_74 ↗
10. Baronio, F., Zucchini, S., Zulian, F., Salerno, M., Parini, R., Cattoni, A., Deodato, F., Gaeta, A., Bizzarri, C., and Gasperini, S. (2022). Proposal of an Algorithm to Early Detect Attenuated Type I Mucopolysaccharidosis (MPS Ia) among Children with Growth Abnormalities. Medicina, 58.10.3390/medicina58010097 ↗
11. Brain and Spinal MR Imaging Findings in Mucopolysaccharidoses: A Review10.3174/ajnr.A2832 ↗
12. Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)10.1542/peds.2007-1350 ↗
13. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
14. The natural history of growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS)10.1016/j.ymgme.2016.01.009 ↗
15. The diagnosis and management of mucopolysaccharidosis type II10.1186/s13052-024-01769-9 ↗
16. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy10.1007/s00431-007-0635-4 ↗
17. Musculoskeletal Manifestations of Sanfilippo Syndrome (Mucopolysaccharidosis Type III)10.1097/BPO.0b013e31821f5ee9 ↗
18. The Morquio a Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects10.1016/j.ymgme.2013.01.021 ↗
19. Long-term outcomes of enzyme replacement therapy from a large cohort of Korean patients with mucopolysaccharidosis IVA (Morquio A syndrome)
20. Neuroimaging Findings in Patients with Mucopolysaccharidosis: What You Really Need to Know10.1148/rg.2016150168 ↗
21. Diagnosing mucopolysaccharidosis IVA10.1007/s10545-013-9587-1 ↗
22. Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): Presentation, diagnosis and management10.1007/s10545-013-9586-2 ↗
23. Current management options for osteonecrosis of the femoral head: Part 1, diagnosis and nonoperative management
24. Enzyme replacement therapy: Efficacy and limitations10.1186/s13052-018-0562-1 ↗
25. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation10.1016/j.joca.2013.08.001 ↗
26. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: Comparison in two siblings10.1016/j.ymgme.2012.12.010 ↗
27. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: A 3-year follow-up
28. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age—A sibling control study10.1111/j.1399-0004.2009.01324.x ↗
29. Enzyme-Replacement Therapy in a 5-Month-Old Boy With Attenuated Presymptomatic MPS I: 5-Year Follow-up10.1542/peds.2009-1728 ↗
30. Montanari, G., Candela, E., Baronio, F., Ferrari, V., Biasucci, G., Lanari, M., and Ortolano, R. (2025). Early-Onset Inherited Metabolic Diseases: When Clinical Symptoms Precede Newborn Screening-Insights from Emilia-Romagna (Italy). Children, 12.10.3390/children12040464 ↗